NCT00281658 - Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2 | Biotech Hunter

Enrollment

444

Participants

Timeline

Start Date

January 2, 2006

Primary Completion Date

June 18, 2010

Study Completion Date

November 23, 2021

Conditions

Neoplasms, Breast

Interventions

DRUG

Lapatinib (GW572016) oral tablets

1500 mg oral daily continuously

DRUG

Paclitaxel infusion

Paclitaxel 80 mg/m2 every 3 weeks, 4th week rest for minimum 6 months

DRUG

Placebo

Paclitaxel Matching Placebo

Trial Locations (54)

10400

Novartis Investigative Site, Bangkok

14029

Novartis Investigative Site, Chernihiv

18009

Novartis Investigative Site, Cherkasy

49055

Novartis Investigative Site, Dnipropetrovsk

50200

Novartis Investigative Site, Chiang Mai

53400

Novartis Investigative Site, Lahore

54600

Novartis Investigative Site, Lahore

69040

Novartis Investigative Site, Zaporizhzhia

100021

Novartis Investigative Site, Beijing

100036

Novartis Investigative Site, Beijing

100071

Novartis Investigative Site, Beijing

100853

Novartis Investigative Site, Beijing

110015

Novartis Investigative Site, Shenyang

116011

Novartis Investigative Site, Dalian

116027

Novartis Investigative Site, Dalian

117997

Novartis Investigative Site, Moscow

125101

Novartis Investigative Site, Moscow

143423

Novartis Investigative Site, Moscow

200032

Novartis Investigative Site, Shanghai

200070

Novartis Investigative Site, Shanghai

200433

Novartis Investigative Site, Shanghai

210002

Novartis Investigative Site, Nanjing

210009

Novartis Investigative Site, Nanjing

250012

Novartis Investigative Site, Jinan

250031

Novartis Investigative Site, Jinan

250117

Novartis Investigative Site, Jinan

300060

Novartis Investigative Site, Tianjin

310022

Novartis Investigative Site, Hangzhou

344037

Novartis Investigative Site, Rostov-on-Don

350001

Novartis Investigative Site, Fuzhou

350014

Novartis Investigative Site, Fuzhou

394062

Novartis Investigative Site, Voronezh

400037

Novartis Investigative Site, Chongqing

420029

Novartis Investigative Site, Kazan'

430030

Novartis Investigative Site, Wuhan

443031

Novartis Investigative Site, Samara

510060

Novartis Investigative Site, Guangzhou

610041

Novartis Investigative Site, Chengdu

710032

Novartis Investigative Site, Xi'an

710061

Novartis Investigative Site, Xi'an

40.050-410

Novartis Investigative Site, Salvador

40285-001

Novartis Investigative Site, Salvador

30150-281

Novartis Investigative Site, Belo Horizonte

59075-740

Novartis Investigative Site, Natal

90610 000

Novartis Investigative Site, Porto Alegre

17210-120

Novartis Investigative Site, Jaú

09060-650

Novartis Investigative Site, Santo André

01221-020

Novartis Investigative Site, São Paulo

03102-002

Novartis Investigative Site, São Paulo

Unknown

Novartis Investigative Site, Kowloon

Novartis Investigative Site, Pokfulam

Novartis Investigative Site, Tuenmen

Novartis Investigative Site, Lahore

Lima 34

Novartis Investigative Site, Lima